SCHEMBL22798201

SCHEMBL22798201

CCCC(=O)Nc1cc(C(=O)NCCOc2ncc(C(F)(F)F)cc2Cl)ccn1

nearest known ligand 0.77

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.77
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
PPARG P37231 4/20 0.42
GPR52 Q9Y2T5 1/20 0.42
MRGPRX4 Q96LA9 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30449855 1.00 SCN9A (0.77) SCN9ANPC1RAB9APPARGGPR52
SCHEMBL28350942 0.95 SCN9A (0.74) SCN9ANPC1RAB9APPARGGPR52
SCHEMBL22797774 0.93 SCN9A (0.79) SCN9APPARGGPR52MRGPRX4MEN1
SCHEMBL22799398 0.92 SCN9A (0.66) SCN9ANPC1RAB9APPARGGPR52
SCHEMBL22797745 0.89 SCN9A (0.82) SCN9APPARGGPR52MRGPRX4KMT2A
SCHEMBL30450684 0.89 SCN9A (0.82) SCN9APPARGGPR52MRGPRX4KMT2A
SCHEMBL22799397 0.88 SCN9A (0.60) SCN9ANPC1RAB9AGPR52MRGPRX4
SCHEMBL22799218 0.88 SCN9A (0.79) SCN9AGPR52MRGPRX4KMT2ALMNA
SCHEMBL22797785 0.87 SCN9A (1.00) SCN9APPARGGPR52MRGPRX4LMNA
SCHEMBL20595173 0.86 SCN9A (0.77) SCN9APPARGGPR52MRGPRX4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885NPC1 743/4885RAB9A 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.